A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R -Roscovitine), administered twice daily for 7 days every 21 days

Charlotte Benson,Jim F. White,J. de Bono,A. O'Donnell,Florence I. Raynaud,C. Cruickshank,H. McGrath,Michael I. Walton,Paul Workman,Stan B. Kaye,Jim Cassidy,A Gianella-Borradori,Ian Judson,C. Twelves

A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R -Roscovitine), administered twice daily for 7 days every 21 days

2007

Charlotte Benson
Jim F. White
J. de Bono
A. O'Donnell
Florence I. Raynaud
C. Cruickshank
H. McGrath
Michael I. Walton
Paul Workman
Stan B. Kaye
Jim Cassidy
A Gianella-Borradori
Ian Judson
C. Twelves

A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R -Roscovitine), administered twice daily for 7 days every 21 days

Keywords:

Immunology
Medicine
Pathology
Cyclin-dependent kinase
Kinase
Pharmacology
Seliciclib
Maximum tolerated dose
R-roscovitine
Skin cancer
Lung cancer
Peripheral blood mononuclear cell
Creatinine
Ovarian cancer
Liver cancer
Rash

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

207

Citations